- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | SynAct Pharma AB: SynAct Pharma publishes Q2 2026 interim results | 105 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2026.
"With new capital secured and active partnering discussions underway, we are positionedto pursue the... ► Artikel lesen | |
| Mi | SynAct Pharma AB: SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil - term sheet signed | 129 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the company has signed... ► Artikel lesen | |
| 05.08. | SynAct Pharma AB: SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation | 518 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued a favorable Decision on Appeal in... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 20.07. | SynAct Pharma AB: SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness | 719 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct" or the "Company") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company developing resolution therapies for inflammatory diseases, today announced that it has... ► Artikel lesen | |
| 29.06. | SynAct Pharma AB: BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study | 763 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through resolution therapy, today provides an update following... ► Artikel lesen | |
| 15.06. | SynAct Pharma AB: Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering | 456 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, reported today that resomelagon in combination... ► Artikel lesen | |
| 12.06. | SynAct Pharma AB: SynAct obtains key US patent for resomelagon securing exclusivity until 2044 | 587 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the United States Patent and Trademark Office (USPTO) have provided the issue notification of US patent 12,661,336 with issue date 23 June 2026... ► Artikel lesen | |
| 11.06. | SynAct Pharma AB: Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) | 429 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) held its Annual General Meeting today, Thursday 11 June 2026, at the offices of MAQS Advokatbyrå in Stockholm. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman... ► Artikel lesen | |
| 27.05. | SynAct Pharma AB: SynAct Pharma publishes Q1 2026 interim results | 359 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2026.
"As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous... ► Artikel lesen | |
| 06.05. | SynAct Pharma AB: SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study | 602 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully completed dosing... ► Artikel lesen | |
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 277 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 539 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 255 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 292 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 557 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen | |
| 06.02. | SynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study | 504 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment... ► Artikel lesen | |
| 30.01. | SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency | 449 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated... ► Artikel lesen | |
| 19.01. | SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO | 256 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand... ► Artikel lesen | |
| 27.11.25 | SynAct Pharma AB: Report from the Extraordinary General Meeting of SynAct Pharma AB | 308 | GlobeNewswire (Europe) | An Extraordinary General Meeting in SynAct Pharma AB (publ) was held today, 27 November 2025, at MAQS Advokatbyrå's premises at Stureplan 19 in Stockholm. Chairperson of the General Meeting was Matilda... ► Artikel lesen | |
| 03.11.25 | SynAct Pharma AB: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion | 377 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has randomized 190 out of 240 patients... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,040 | -1,17 % | Bayer ist mehr als die Roundup-Wette | Bayer hat an der Börse lange fast nur über ein einziges Thema funktioniert: Glyphosat. Gute Pharmadaten, Agrarwachstum oder Sparprogramme wurden regelmäßig von neuen US-Rechtsrisiken überlagert. Im... ► Artikel lesen | |
| ABBVIE | 227,10 | +0,09 % | Warum Eli Lilly 3,8 Milliarden US-Dollar auf Psychedelika setzt - und Emyria plötzlich an einem entscheidenden Engpass sitzt | ||
| ELI LILLY | 1.075,00 | +0,04 % | Eli Lillys Milliarden-Deal verändert den Psychedelika-Markt: Warum Emyria Limited mit seiner Klinik-Infrastruktur in den Fokus rückt | ||
| MERCK & CO | 130,78 | +0,14 % | Den Krebs im Fokus: Merck & Co., Vidac Pharma und AstraZeneca! | Aktuell gibt es laut der Internationalen Krebsforschungsagentur (IARC) der WHO rund 20,6 Millionen Krebsfälle. Die Zahl der Todesfälle wird auf jährlich etwa 10 Millionen Menschen geschätzt. In den... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 57,51 | +0,19 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| INNOCAN PHARMA | 1,355 | -1,81 % | SCHOCKMELDUNG bei InnoCan Pharma: 5,43% Absturz und neues All-Time-Low! | ||
| DOCMORRIS | 10,660 | +0,19 % | Ihre wichtigsten Termine: Spannende Zahlen von: Analog Devices, DocMorris, Carlsberg, Geberit & Straumann | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: US0326541051,DK0010181759,DE0007314007... ► Artikel lesen | |
| INCYTE | 110,00 | +0,50 % | Incyte: H.C. Wainwright bekräftigt Rating nach Daten zu Krebsmedikament | ||
| SINOPHARM | 1,801 | -1,64 % | SINOPHARM (01099): CONNECTED TRANSACTION DISPOSAL OF EQUITY INTERESTS IN CHINA NATIONAL MEDICINES GUORUI PHARMACEUTICAL CO., LTD. | ||
| HAPPY BELLY FOOD GROUP | 1,000 | +1,01 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness QSR Announces the Grand Opening of Its Newest Location in Sylvan Lake, Alberta | Toronto, Ontario--(Newsfile Corp. - August 21, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,500 | 0,00 % | Vergiss Zulassungen! Wer zahlt für die Therapie? Diese 3 Biotech-Aktien zeigen, worauf es jetzt wirklich ankommt | ||
| HIGH TIDE | 2,085 | -0,95 % | High Tide Inc.: High Tide Announces Voting Results of Annual General and Special Meeting of Shareholders | CALGARY, AB, Aug. 12, 2026 /PRNewswire/ -- High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 244,00 | -0,81 % | $100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| JAZZ PHARMACEUTICALS | 218,30 | +0,28 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio | Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy
Leverages Jazz development expertise and commercial strength in... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 13,050 | -1,51 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen |
SYNACT PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,80 % bei einem Aktienkurs von 1,756 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.